Clinical Trial Update: Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assesses safety and immunogenicity of intradermal versus subcutaneous dosing of Menomune for meningococcal infections and meningitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Infections

Drugs mentioned

• Menomune (Meningococcal polysaccharide vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningococcal Infections, Meningitis | Phase 4 | Status: COMPLETED | Results posted: 2009-04-30